• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

The Superiority of IFN-lambda as a Therapeutic Candidate to Control Acute Influenza Viral Lung Infection

tetano

Editor, Senior Moderator
Am J Respir Cell Mol Biol. 2016 Sep 15. [Epub ahead of print]
[h=1]The Superiority of IFN-lambda as a Therapeutic Candidate to Control Acute Influenza Viral Lung Infection.[/h] Kim S[SUP]1[/SUP], Kim MJ[SUP]2[/SUP], Kim CH[SUP]3[/SUP], Kang JW[SUP]4[/SUP], Shin HK[SUP]5[/SUP], Kim DY[SUP]6[/SUP], Won TB[SUP]7[/SUP], Han DH[SUP]8[/SUP], Rhee CS[SUP]9[/SUP], Yoon JH[SUP]10[/SUP], Kim HJ[SUP]11[/SUP].
[h=3]Author information[/h]

[h=3]Abstract[/h] [h=4]RATIONALE AND OBJECTIVES:[/h] Here we studied the interferon (IFN)-regulated innate immune response against influenza A virus (IAV) infection in the mouse lung and the therapeutic effect of IFN-λ2/3 in acute IAV lung infection. .
[h=4]METHODS:[/h] For viral infections, IAV (WS/33, H1N1, PR8 H1N1, H5N1) were inoculated into WT mice by intranasal delivery and IAV mRNA level and viral titer were measured. To compare the antiviral effect of IFNs in vivo lung, neutralizing antibodies and recombinant IFNs were used.
[h=4]MEASUREMENT AND MAIN RESULTS:[/h] Following intranasal inoculation of IAV into mice, viral infection peaked at 7 days post of infection (dpi) and the IAV titer also reached its peak at this time. We found that IFN-β and IFN-λ2/3 were preferentially induced after IAV infection and the IFN-λ2/3-mediated innate immune response was specifically required for the induction of IFN-stimulated genes (ISGs) transcription in the mouse respiratory tract. Neutralization of secreted IFN-λ2/3 aggravated acute IAV lung infection in mice with intact IFN-β induction; consistent with this finding, the transcription of ISGs was significantly reduced. Intranasal administration of IFN-λ2/3 significantly suppressed various strains of IAV infection including WS/33 (H1N1), PR (H1N1), and H5N1 in the mouse lung and was accompanied by greater up-regulation of ISGs.
[h=4]CONCLUSION:[/h] Our data indicate that the IFN-λ2/3-mediated innate immune response is necessary to protect the lungs from IAV infection and intranasally delivered IFN-λ2/3 has the potential to be a useful therapeutic strategy for treating acute IAV lung infection.


[h=4]KEYWORDS:[/h] Acute Viral Lung Infection; Influenza A virus; Interferon-Lambda; Interferon-beta

PMID: 27632156 DOI: 10.1165/rcmb.2016-0174OC
[PubMed - as supplied by publisher]
 
Back
Top Bottom